We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Insights from a rare myeloproliferative neoplasm with coexisting BCR‐ABL1 fusion gene, CALR, and TET2 mutations treated with nilotinib and ruxolitinib.
- Authors
Huo, Li; Xie, Jundan; Wang, Qian; Shen, Hongjie; Ding, Zixuan; Wen, Lijun; Zeng, Zhao; Xu, Yi; Ruan, Changgeng; Chen, Suning; Xue, Mengxing
- Abstract
Myeloproliferative neoplasms (MPNs) with concurrent BCR‐ABL1 fusion gene and CALR mutation are especially rare. We report a patient with coexisting BCR‐ABL1 fusion gene, CALR, and TET2 mutations who was treated with the combination of the second‐generation TKI nilotinib and JAK1/JAK2 inhibitor ruxolitinib.
- Subjects
GENE fusion; MYELOPROLIFERATIVE neoplasms; RUXOLITINIB; NILOTINIB; GENETIC mutation; MYELOFIBROSIS
- Publication
Clinical Case Reports, 2023, Vol 11, Issue 1, p1
- ISSN
2050-0904
- Publication type
Case Study
- DOI
10.1002/ccr3.6801